Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00643669 | 24 Hour IOP Lowering Efficacy of AL-3789 | PHASE2 | COMPLETED | 25 | — | — | Feb 1, 2008 | - | Nov 29, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| AL-3789 | EXPERIMENTAL | AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye |
| No treatment | NO_INTERVENTION | Fellow eye, as randomized |
| Name | Type | Description |
|---|---|---|
| AL-3789 Sterile Suspension | DRUG | Single administration by anterior juxtascleral depot |
Inclusion Criteria: * Diagnosis of open-angle glaucoma and treated for at least 30 days prior to Screening Visit with a topical prostaglandin analog as monotherapy. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Pregnant, intend to become pregnant, breastfeeding. * D...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |